Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
October 06, 2020 09:30 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is...
Derm-Biome Pharmaceuticals, Inc raises pre-seed funding, spins out new company focused on chronic inflammatory diseases
July 02, 2020 11:00 ET
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 02, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin diseases and healthy ageing,...
5 Tips to Improve Nail Psoriasis at Home; American Academy of Dermatology
June 11, 2020 14:31 ET
|
American Academy of Dermatology
ROSEMONT, Ill., June 11, 2020 (GLOBE NEWSWIRE) -- Approximately 7.5 million people in the U.S.1 have psoriasis, a chronic inflammatory disease that mostly affects the skin and joints but could also...
Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
January 15, 2020 02:39 ET
|
Dermavant Sciences, Inc.
JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan Dermavant to receive an upfront payment of $60 million,...
Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
June 10, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc....
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
June 05, 2019 08:00 ET
|
Dermavant Sciences, Inc.
Top-line data is anticipated in the first half of 2020If PSOARING trials are successful, a New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA) is anticipated in 2021 ...
Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
May 14, 2019 09:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Biopsy data support strong clinical effect observed in Phase 2 trials with SNA-120 -- Following Positive End-of-Phase 2 meeting with FDA, Sienna continues toward enrolling first patient in Phase...
Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results
May 08, 2019 16:05 ET
|
Sienna Biopharmaceuticals, Inc.
-- Company Completed Positive End-of-Phase 2 Meeting with FDA for SNA-120 in Psoriasis WESTLAKE VILLAGE, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA)...
Sandoz Canada receives Health Canada approval for Erelzi® (etanercept) in the Treatment of Psoriatic Arthritis (PsA) in Adult Patients
January 21, 2019 08:31 ET
|
Sandoz Canada
Boucherville, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Erelzi is the only etanercept biosimilar to be indicated for reducing the signs and symptoms of psoriatic arthritis (PsA) in adult patients.Up to...
AllergyStore.com to Expand Product Range to Meet "High Demand" Spring Allergy Season
December 10, 2018 09:51 ET
|
AllergyStore.com
Company Will Carry Bedding, Clothing, Home Goods, and Other Products to Help Adults and Children Overcome Allergy- and Asthma-related Symptoms Lynbrook, NY, Dec. 10, 2018 (GLOBE NEWSWIRE) --...